Objectives: To study the long-term efficacy and safety of the drug finasteride (Proscar®) for benign prostatic hyperplasia and to evaluate whether an improved effect beyond 1 year was due to continuous selection of ‘responders’. We also wanted to investigate whether drop-outs differed in short-term responses to those completing the trial. Methods: A total of 182 patients were enrolled in a double-blind randomized multicenter study with the drug finasteride. After 6 months, all patients were treated with active drug for up to 6 years. Ninety-nine of the patients (54.5%) were still in the trial at its closure. Results: Patients treated with active drug had a decrease in prostate size of around 27% at 6 months, a figure reached by the ex-placebo group at 12 months. At 6 years, both groups had a reduction in prostate size of 21% as measured from baseline. At 6 months, urinary flow had improved by a mean of 2.4 ml/s in the finasteride group and reached an improvement of 2.8 ml/s in the ex-placebo group at 12 months. At 6 years, the flow had improved by 2.2 ml/s in both groups combined as compared to baseline data. The symptom score was improved by 3.4 points in the finasteride group at 6 months and by 2.6 points in the ex-placebo group at 12 months; both values were then maintained over 6 years. Conclusion: In responders (those completing the 6-year trial), finasteride appeared to be a safe drug which reduced the prostate size by 20–25% within 6 months, with a simultaneous 30% improvement of objective and subjective symptoms and a 2.2 ml/s improvement in urinary flow rate. The improvements were maintained for at least 6 years; however, further improvement beyond 6 months of therapy was not likely to occur.

1.
The Finasteride Study Group: Finasteride (MK-906) in the treatment of benign prostatic hyperplasia. Prostate 1993;22:292–299.
2.
Caine M, Perlberg S, Meretyk S: A placebo-controlled double-blind study of the effect of phenoxybenzamine in benign prostatic obstruction. Br J Urol 1978;50:551–554.
3.
Lepor H, Baumann M, Shapiro E: The alpha adrenergic binding properties of terazosin in the human prostate adenoma and canine brain. J Urol 1988;140:664–667.
4.
Bruchovsky N, Wilson JD: The conversion of testosterone to 5α-androstan-17β-ol-3-one by rat prostate. J Biol Chem 1968;43:2012–2021.
5.
Snochowski M, Pousette Å, Ekman P, Bression D, Andersson L, Högberg B, Gustafsson JÅ: Characterization and measurement of the androgen receptor in human benign prostatic hyperplasia and prostatic carcinoma. J Clin Endocrinol Metab 1977;45:920–930.
6.
Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, et al.: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Engl J Med 1992;327:1185–1191.
7.
Moore E, Bracken B, Bremner W, Geller J, Imperato-McGinley J, McConnell J, Roy J, Tenover J, Vaughan D, Pappas F: Proscar: Five-year experience. Eur Urol 1995;28:304–309.
8.
Beisland HO, Binlowitz B, Brekkan E, Ekman P, et al.: Scandinavian clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 1992;22:271–277.
9.
Lepor H: Long term efficacy and safety in patients with benign prostatic hyperplasia. Terazosin Research Group. Urology 1995;45:406–413.
10.
Boyarsky S, Jones G, Paulson DF, Prout GR Jr: A new look at bladder neck obstruction by the Food and Drug Administration regulators: Guidelines for investigation of benign prostatic hypertrophy. Trans Am Assoc Genitourin Surg 1977;68:29–32.
11.
Boyle P, Gould L, Roehrborn C: Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: Meta-analysis of randomized clinical trials. Urology 1996;48:398–405.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.